香豆素类植物雌激素防治骨质疏松的分子生物学机制研究
|
摘要
目的:随着老龄化社会的到来,很多与增龄有关的老年病越来越受到人们的重视。骨质疏松症是一种增龄性病变,目前全世界约有2亿患者,其发病率跃居常见病、多发病的第7位。据2000年普查数据显示,我国约有骨质疏松症患者8800万,占总人口的6.6%。60~69岁老年妇女骨质疏松发生率高达50%~70%,老年男性发生率为30%左右。每年的医疗费用按最保守估计也需要50亿人民币。骨质疏松引起的骨折及其并发症严重影响着中老年人的生活质量,成为全球性的公共卫生问题之一。因此,有效预防与治疗骨质疏松症已成为当务之急。现代医学用于骨质疏松症防治的药物主要为骨吸收抑制剂和骨形成促进剂2类。目前最常用的是“激素替代疗法”,此种疗法虽然可以防治绝经后妇女骨量丢失,提高骨密度,但长期应用有促进子宫内膜增生、肝功损害、静脉栓塞、血管疾病以及增加乳腺癌的发生率等不良后果。
植物雌激素(phytoestrogen, PE)是存在于植物、水果和蔬菜中的一类天然的、结构及生物活性均类似于雌激素的非甾体类化合物,具有弱雌激素活性,为杂环多酚类化合物。PE可与雌激素受体结合,对内源性雌激素起双向调节作用,其在改善围绝经期症状、降低血脂水平、防治骨质疏松、预防尿失禁等方面有着有益作用,且没有因服用雌激素而出现的各种不良后果。所以植物雌激素在防治骨质疏松症方面代替雌激素将是一个很好选择。
中药在补骨方面有很好的疗效。中药补骨脂为豆科植物补骨脂Psoralea corylifolia L.的干燥成熟果实,有补肾壮阳,温脾止泻之功效。从补骨脂的现代药理研究来看,补骨脂水提物对骨转换的影响可能包括抑制骨吸收和促进骨形成两方面。并对雌激素依赖性骨丢失具有防治作用。补骨脂丙酮提取物能增加大鼠骨强度,提高血中磷酸盐水平,用补骨脂复方制剂给模型大鼠灌胃,能使其血清碱性磷酸酶降至正常水平,显著降低尿中Ca/cr和HOP/cr水平,并显著抑制骨吸收,使大鼠骨代谢处于骨形成大于骨吸收的平衡状态。补骨脂的主要化学成分是香豆素类和黄酮类化合物。补骨脂素是补骨脂的主要活性成分之一。已经证明补骨脂素在体外促进成骨细胞增殖、分化及合成1型胶原,但其对成骨细胞内信号系统的作用机制尚不清楚。本研究在前人研究基础上对补骨脂素防治骨质疏松的分子生物学机制进行探讨,以期为临床防治骨质疏松提供可参考的理论依据,并为研制防治骨质疏松药物提供了有效的作用靶点。
本研究探讨香豆素类植物雌激素防治骨质疏松的分子生物学机制。
方法:
1采用改良的组织块培养法,分离培养新生(24h)SD大鼠颅骨成骨细胞。将不同浓度的异欧前胡素(10-9 mol/L~10-5 mol/L)加入到培养成骨细胞的培养基中,用倒置显微镜观察细胞形态和数量的改变。
2采用噻唑蓝比色(MTT)法,以雌二醇(estradiol,E2)为阳性对照,考察加药后,异欧前胡素24h,48h,72h时对成骨细胞增殖的影响。
3采用对硝基二钠基质动力学法(pNPP),以雌激素为阳性对照,检测加药后,异欧前胡素在24h,48h,72h时对成骨细胞碱性磷酸酶活性的影响。
4采用逆转录聚合酶链反应(reverse transcriptase PCR, RT-PCR)方法,以雌激素为阳性对照,检测含有补骨脂素培养基的成骨细胞在72小时骨保护素(OPG)和核因子κB受体激活因子配体(RANKL)mRNA的表达。
5采用免疫组织化学(immunohistochemistry)方法,雌激素为阳性对照组,在倒置相差显微镜下观察含补骨脂素的培养基中骨形态发生蛋白2(BMP-2)的表达。
结果:
1阳性对照雌激素组对成骨细胞增殖与分化的影响
1.1阳性对照雌激素组细胞形态学观察刚接种的成骨细胞成球形,悬浮于培养液中,逐渐沉降贴壁,24 h细胞贴壁展开。展开细胞形态不规则,呈多角形,培养72 h~96 h,细胞为长梭形、条索状,融合成片,分界较为模糊。培养120 h,细胞呈铺路石状。如果继续培养,细胞逐渐形成细胞小结,随后胶原堆积,钙盐沉积,形成不透光的矿化结节。连续培养20代,可见细胞体积增大,胞质稀薄,细胞分裂速度大大下降等细胞衰老的表现。雌激素处理组与空白对照组相比,在72 h~96 h时,细胞更加密集,细胞间隙少,形态无明显差异。
1.2阳性对照雌激素组对大鼠成骨细胞增殖的影响
大鼠成骨细胞在含有不同浓度雌激素培养基中培养24 h ,在浓度为1×10-5 mol/L,1×10-7 mol/L和1×10-8 mol/L有促增殖作用(P<0.05);培养48 h,浓度为1×10-6 mol/L, 1×10-8 mol/L和1×10-9 mol/L有促增殖作用(P<0.05);培养72 h ,浓度为1×10-5 mol/L~1×10-7 mol/L与空白对照组比较有显著的促增殖作用(P<0.01)。
1.3阳性对照雌激素组对大鼠成骨细胞碱性磷酸酶活性的影响
培养48 h ,与空白对照组比较,雌激素组浓度为1×10-5 mol/L~1×10-6 mol/L有明显的增强碱性磷酸酶活性的作用(P<0.05);培养72 h ,浓度为1×10-6 mol/L~1×10-9 mol/L有增强碱性磷酸酶活性的作用(P<0.05)。
2异欧前胡素对成骨细胞增殖和分化的影响
2.1异欧前胡素组细胞形态学观察与阳性对照雌激素组类似。
2.2异欧前胡素对大鼠成骨细胞增殖的影响
大鼠成骨细胞在含有不同浓度异欧前胡素培养基中培养48h,浓度为1×10-9 mol/L~1×10-8 mol/L有促增殖作用(P<0.05);72h时,浓度为1×10-8 mol/L~1×10-7 mol/L有促增殖作用(P<0.05)。
2.3异欧前胡素对大鼠成骨细胞碱性磷酸酶活性的影响培养48小时,与空白对照组比较,异欧前胡素各浓度组均没有明显差别(P>0.05)。72小时,与空白对照组比较浓度1×10-6mol/L~1×10-5mol/L的异欧前胡素能够提高碱性磷酸酶的活性,促进成骨细胞的分化。
3补骨脂素对大鼠成骨细胞分泌的OPG mRNA ,RANKLmRNA表达的影响
3.1补骨脂素对大鼠成骨细胞分泌的OPG mRNA表达的影响
培养72小时后,空白对照组的OPG mRNA /GAPDH mRNA的相对表达量为0.6084,阳性对照组雌二醇组的OPG mRNA /GAPDH mRNA的相对表达量为1.3395,与空白对照组比较促进了OPGmRNA的表达,差异有显著性(P<0.05);补骨脂素组的OPGmRNA /GAPDHmRNA的相对表达量为1.0794,与空白对照组比较促进了OPGmRNA的表达,差异有显著性(P<0.05)。
3.2补骨脂素对大鼠成骨细胞分泌的RANKL mRNA表达的影响
培养72小时后,空白对照组的RANKL mRNA /GAPDH mRNA的相对表达量为1.0203;阳性对照组雌二醇组的RANKL mRNA /GAPDH mRNA的相对表达量为0.8907,与空白对照组比较抑制了RANKLmRNA的表达,差异有显著性(P<0.05);补骨脂素组的RANKLmRNA /GAPDHmRNA的相对表达量为0.8374,与空白对照组比较抑制了RANKLmRNA的表达,差异有显著性(P<0.05),与雌激素组比较无明显差别。
各组OPG/RANKL比值的比较结果是:补骨脂素组与空白对照组比较OPG/RANKL值增加,差别有统计学意义(P<0.05)。
4补骨脂素对大鼠成骨细胞分泌骨形态发生蛋白(BMP-2)的影响
通过免疫组化方法,在倒置相差显微镜下观察,每个低倍镜下(200×)数阳性细胞数,补骨脂素组平均每个低倍镜视野下细胞阳性率为86.67%,雌激素组为93.33%,空白对照组为33.33%,经统计学分析,补骨脂素组与空白对照组比较,BMP-2的表达明显升高,与雌激素组比较无明显差别。
结论
1异欧前胡素作用48小时后,浓度为1×10-9 mol/L~1×10-8 mol/L有促增殖作用(P<0.05);72h时,浓度为1×10-8 mol/L~1×10-7 mol/L有促增殖作用(P<0.05)。
2异欧前胡素作用72小时,浓度1×10-6mol/L~1×10-5mol/L的异欧前胡素能够提高碱性磷酸酶的活性,促进成骨细胞的分化。
3补骨脂素能够上调OPGmRNA的表达,下调RANKLmRNA的表达并使得OPG/RANKL比值增大,这说明香豆素类化合物有可能是通过促进骨形成抑制骨吸收达到防治骨质疏松目的。
4补骨脂素与空白对照组比较能促进成骨细胞分泌骨形态发生蛋白,有统计学意义。说明补骨脂素有可能是通过促进细胞分泌骨形态发生蛋白来发挥其促进骨形成作用。
5从分子生物学角度为香豆素类化合物防治骨质疏松提供一个理论支持。
Objective: With the arrival of the aging society, more and more attention is drawn to the aging problems. Osteoporosis was an important disease affecting human health,which is related to aging. Till now about 2 billion people are infected with Osteoporosis in the world, and its incidence rate is high. A primary analysis of the main statistics of 2000 census, in China about 8800 million people(about occupide 6.6% of population) suffering from Osteoporosis,especially thoses people whose age is in 60~69.it is estimated that the medical care expenses on the treatment of Osteoporosis is about 50 billion rmb at least every year. Osteoporosis, along with it's searious complication and fractures, is severly threatening the wrinkly's health. So it is urgent affairs to find out effective drugs and methods to prevent and treat osteoporosis. Bone absorptioninhibitor drugs and bone formationacceleration drugs are two kinds of anti-osteoporosis drugs. Hormone Replacement Therapy is more commonly used , which could decrease bone mineral loss in Post-menopause Women and improve the density of bone, but promote endometrial hyperplasia, liver damage, venous embolization,vessels diseases and breast cancer.
Phytoestrogen (PE) is a group of natural non steroid compound which displays estrogen like activity because of their structural similarity to human estrogens and exhibits high affinity binding to estrogen receptor beta. PE could improvement perimenopause syndrome,decrease the blood lipid level, prevent osteoprosis and urinary incontinence. Substitute for estrogen in preventing osteoprosis is a hopeful application field for PE. Traditional Chinese drugs Psoralea fruit can improve Yangqi of spleen and kidney. Modern pharmacological research shows the water soluble extractive of Psoralea has the effect on the bone turnover.The acetone-extract from Psoralea fruits can increase bone strength,improve the phosphate in blood. The model of rats osteoprosis were orally injected into the stomach by psoralea compound preparation, decrease alkaline phosphatase(ALP) leavel to normal, decrese Ca/cr and HOP/cr leavels in urine, inhibit absorbtion of bone, the rate of bone formation is eventually greater than bone absorption. Psoralen was one of active component in psoralea. Psoralen has the effects on stimulating the proliferation and maturation of cultured osteoblasts in vitro and promoting typeⅠcollagen (COLI)synthesis. The intracellular signal transduction mechanism of the psoralen to promote the growth of the osteoblasts is not clear. Based on the previous research, we explore the molecular mechanisms biology for psoralen preventing osteoprosis. In order to provide theoretical basis for clinical preventing osteoprosis.
Methods:
1 Cell culture: Improved tissue block culture, to demesh and cultivate osteoblast from cranial bone of newly born SD rats.By ading different concentrations of isoimperatorin (1×10-5 mol/L ~1×10-9 mol/L ) to the nutrient medium of osteoblast it can be observed the alteration of the shape and quantity of cells using inverted phase contrast microscope.
2 Cell proliferation: It can be inspected that the effect of isoimperatorin on the proliferation of osteoblast in 24 h ,48 h and 72 h by MTT methods with the contrast of the group of dealing with estrogen and control group.
3 Cell differentiation: It can be detected that the change of the activity of ALP in osteoblast of the group of dealing with isoimperatorin in24h,48h,72h byρ-nitrophenyl phosphate(рNPP) disodium matrix dynamics methods with the contrast of the group of dealing with estrogen.
4 Cell factors: It can be detected that the expression of Osteoprotegerin (OPG) mRNA, and receptor activator of nuclear factor–κB(RANKL)mRNA of the group of dealing with psoralen in 72 h via RT-PCR with the contrast of the group of dealing with estrogen and control group.
5 Cell protein: It can be detected that the expression of Bone morphogenetic protein (BMP-2) of the group of dealing with psoralen in 72h via immunohistochemistry with the contrast of the group of dealing with estrogen and control group.
Results:
1 The effect of estrogen,as positive control ,on the proliferation and differentiation of the osteoblast
1.1 Cell morphology observation of estrogen group,as positive control
The osteoblast cells which is inoculated is globular at first and then floats in culture fluid . Subsequently it is adherent,it will expand in 24 h.The shape of expanded cell is irregular with a appearance of triangle. After 48 h~96 h,osteoblast shows on long fusiform and trabs shape and mixes together and the boundary is vague between cells. Osteoblast shows slabstone shape after 120 h. If you keep on culturing cell, cells will form cell nodule and opaque mineral nodus with accumulating of collagen and calcium salts. When you culture the 20th generation, the volume of the cell is larger than normal, periplast is more subtile than normal,the speed of cleavage is slower and other phenomena which are signs of aging. Osteoblasts are more intensive in estrogen than the blank group. Also its intercellular space is smaller than those of the blank.
1.2 The effect of estrogen,as positive control on the proliferation of osteoblast
After being cultivated 24 h ,contrasted with control group, the concentrations of 1×10-5mol/L, 1×10-7 mol/L, 1×10-8 mol/L can promote the proliferation of osteoblast (P<0.05); After being cultivated 48 h, the concentrations of 1×10-6mol/L,1×10-8 mol/L,1×10-9mol/L can urge the proliferation of osteoblast (P<0.05); After being cultivated 72 h, the concentratons of 1×10-5 mol/L~1×10-7 mol/L estrogen can promote the proliferation of osteoblast (P<0.05) .
1.3 The effect of estrogen on the ALP of osteoblast
After being cultivated 48 h, contrasted with control group, the concentratons of 1×10-5 mol/L~1×10-6 mol/L can promote the differentiation of osteoblast (P<0.05); after being cultivated 72 h, 1×10-5mol/L~1×10-6mol/L concentrations can urge the differentiation of osteobalst(P<0.05)
2 The effect of isoimperatorin ,as one of the phytoestrogen ,on the proliferation and differentiation of the osteoblast
2.1 Cell morphology observation of the isopsoralen group The phenomenon is similar to estrogen group.
2.2 The effect of isoimperatorin on the proliferation of osteoblast After cultivated 24 h ,contrasted with control group, none of the concentration can promote the proliferation of osteoblast (P>0.05);After cultivated 48h,1×10-9mol/L~1×10-8mol/L concentrations can urge the proliferation of osteoblast(P<0.05);after cultivated 72h, 1×10-8mol/L~1×10-7mol/L concentration can urge the proliferation of osteoblast(P<0.05).
2.3 The effect of isopsoralen on the ALP of osteoblast Contrasted with control group, after cultivated 72h 1×10-6 mol/L~1×10-5mol/L can urge the differentiation of osteobalst(P<0.05).
3 The effect of psoralen on the expression of OPG mRNA in osteobalst
After cultivated 72 h ,the relative quantity of OPG mRNA/GAPDH mRNA expressions in the blank group, in the psoralen group and in the estrogen group are 0.6048, 1.0794 and 1.3395. There is significant difference between psoralen group and the blank group(P<0.05). The expression of OPG mRNA in estrogen group is higher than that in black group(P<0.05). There is no significant difference between estrogen group and psoralen group.
4 The effect of paoralen on the expression of RANKL mRNA in osteobalst
After cultivated 72 h ,the relative quantity of RANKLmRNA/GAPDHmRNA expressions in the blank group ,in the psoralen group and in the estrogen group are 1.0203, 0.8374 and 0.8907. There is significant difference between psoralen group and the blank group(P<0.05). The expression of RANKLmRNA in estrogen group is higher than that in black group(P<0.05). There is no significant difference between estrogen group and psoralen group.
5 The effect of paoralen on the relative quantity of OPG/RANKL in osteobalst
After cultivated 72 h, the relative quantity of VOPG / VRANKL in the blank group ,in the psoralen group and in the estrogen group are 0.599, 1.282 and 1.513. There is significant difference between psoralen group and the blank group(P<0.05). psoralen increased VOPG / VRANKL.
6 Effects of psoralen on the expression of bone morphogenetic protein 2 of osteoblast
the expression of bone morphogenetic protein 2 was tested by immunohistochemistry method.The posotive rates of osteoblast cells in psoralen group is 86.67%, 93.33% in E2 and 33.33% in black group. to compare the black group , psoralen can significantly enhance the expression of BMP-2.
Conclusion:
1 Certain dose of isopsoralen as phytoestrogen, can promote the proliferation of osteoblast.
2 Certain dose of isopsoralen urge the differentiation of osteoblast.
3 The influence of psoralen on bone may be achieved through the pathway of promoting bone formation and inhibiting bone absorption.
4 The influence of psoralen on bone maybe achieved through increasing the expression of OPG mRNA , decreasing the expression of RANKL mRNA,and increasing the rate of VOPG / VRANKL.
5 BMP may be the critical protein in the effection of Phytoestrogen on preventing osteoprosis. The influence of psoralen on bone maybe achieved through increasing the expression of BMP-2
植物雌激素(phytoestrogen, PE)是存在于植物、水果和蔬菜中的一类天然的、结构及生物活性均类似于雌激素的非甾体类化合物,具有弱雌激素活性,为杂环多酚类化合物。PE可与雌激素受体结合,对内源性雌激素起双向调节作用,其在改善围绝经期症状、降低血脂水平、防治骨质疏松、预防尿失禁等方面有着有益作用,且没有因服用雌激素而出现的各种不良后果。所以植物雌激素在防治骨质疏松症方面代替雌激素将是一个很好选择。
中药在补骨方面有很好的疗效。中药补骨脂为豆科植物补骨脂Psoralea corylifolia L.的干燥成熟果实,有补肾壮阳,温脾止泻之功效。从补骨脂的现代药理研究来看,补骨脂水提物对骨转换的影响可能包括抑制骨吸收和促进骨形成两方面。并对雌激素依赖性骨丢失具有防治作用。补骨脂丙酮提取物能增加大鼠骨强度,提高血中磷酸盐水平,用补骨脂复方制剂给模型大鼠灌胃,能使其血清碱性磷酸酶降至正常水平,显著降低尿中Ca/cr和HOP/cr水平,并显著抑制骨吸收,使大鼠骨代谢处于骨形成大于骨吸收的平衡状态。补骨脂的主要化学成分是香豆素类和黄酮类化合物。补骨脂素是补骨脂的主要活性成分之一。已经证明补骨脂素在体外促进成骨细胞增殖、分化及合成1型胶原,但其对成骨细胞内信号系统的作用机制尚不清楚。本研究在前人研究基础上对补骨脂素防治骨质疏松的分子生物学机制进行探讨,以期为临床防治骨质疏松提供可参考的理论依据,并为研制防治骨质疏松药物提供了有效的作用靶点。
本研究探讨香豆素类植物雌激素防治骨质疏松的分子生物学机制。
方法:
1采用改良的组织块培养法,分离培养新生(24h)SD大鼠颅骨成骨细胞。将不同浓度的异欧前胡素(10-9 mol/L~10-5 mol/L)加入到培养成骨细胞的培养基中,用倒置显微镜观察细胞形态和数量的改变。
2采用噻唑蓝比色(MTT)法,以雌二醇(estradiol,E2)为阳性对照,考察加药后,异欧前胡素24h,48h,72h时对成骨细胞增殖的影响。
3采用对硝基二钠基质动力学法(pNPP),以雌激素为阳性对照,检测加药后,异欧前胡素在24h,48h,72h时对成骨细胞碱性磷酸酶活性的影响。
4采用逆转录聚合酶链反应(reverse transcriptase PCR, RT-PCR)方法,以雌激素为阳性对照,检测含有补骨脂素培养基的成骨细胞在72小时骨保护素(OPG)和核因子κB受体激活因子配体(RANKL)mRNA的表达。
5采用免疫组织化学(immunohistochemistry)方法,雌激素为阳性对照组,在倒置相差显微镜下观察含补骨脂素的培养基中骨形态发生蛋白2(BMP-2)的表达。
结果:
1阳性对照雌激素组对成骨细胞增殖与分化的影响
1.1阳性对照雌激素组细胞形态学观察刚接种的成骨细胞成球形,悬浮于培养液中,逐渐沉降贴壁,24 h细胞贴壁展开。展开细胞形态不规则,呈多角形,培养72 h~96 h,细胞为长梭形、条索状,融合成片,分界较为模糊。培养120 h,细胞呈铺路石状。如果继续培养,细胞逐渐形成细胞小结,随后胶原堆积,钙盐沉积,形成不透光的矿化结节。连续培养20代,可见细胞体积增大,胞质稀薄,细胞分裂速度大大下降等细胞衰老的表现。雌激素处理组与空白对照组相比,在72 h~96 h时,细胞更加密集,细胞间隙少,形态无明显差异。
1.2阳性对照雌激素组对大鼠成骨细胞增殖的影响
大鼠成骨细胞在含有不同浓度雌激素培养基中培养24 h ,在浓度为1×10-5 mol/L,1×10-7 mol/L和1×10-8 mol/L有促增殖作用(P<0.05);培养48 h,浓度为1×10-6 mol/L, 1×10-8 mol/L和1×10-9 mol/L有促增殖作用(P<0.05);培养72 h ,浓度为1×10-5 mol/L~1×10-7 mol/L与空白对照组比较有显著的促增殖作用(P<0.01)。
1.3阳性对照雌激素组对大鼠成骨细胞碱性磷酸酶活性的影响
培养48 h ,与空白对照组比较,雌激素组浓度为1×10-5 mol/L~1×10-6 mol/L有明显的增强碱性磷酸酶活性的作用(P<0.05);培养72 h ,浓度为1×10-6 mol/L~1×10-9 mol/L有增强碱性磷酸酶活性的作用(P<0.05)。
2异欧前胡素对成骨细胞增殖和分化的影响
2.1异欧前胡素组细胞形态学观察与阳性对照雌激素组类似。
2.2异欧前胡素对大鼠成骨细胞增殖的影响
大鼠成骨细胞在含有不同浓度异欧前胡素培养基中培养48h,浓度为1×10-9 mol/L~1×10-8 mol/L有促增殖作用(P<0.05);72h时,浓度为1×10-8 mol/L~1×10-7 mol/L有促增殖作用(P<0.05)。
2.3异欧前胡素对大鼠成骨细胞碱性磷酸酶活性的影响培养48小时,与空白对照组比较,异欧前胡素各浓度组均没有明显差别(P>0.05)。72小时,与空白对照组比较浓度1×10-6mol/L~1×10-5mol/L的异欧前胡素能够提高碱性磷酸酶的活性,促进成骨细胞的分化。
3补骨脂素对大鼠成骨细胞分泌的OPG mRNA ,RANKLmRNA表达的影响
3.1补骨脂素对大鼠成骨细胞分泌的OPG mRNA表达的影响
培养72小时后,空白对照组的OPG mRNA /GAPDH mRNA的相对表达量为0.6084,阳性对照组雌二醇组的OPG mRNA /GAPDH mRNA的相对表达量为1.3395,与空白对照组比较促进了OPGmRNA的表达,差异有显著性(P<0.05);补骨脂素组的OPGmRNA /GAPDHmRNA的相对表达量为1.0794,与空白对照组比较促进了OPGmRNA的表达,差异有显著性(P<0.05)。
3.2补骨脂素对大鼠成骨细胞分泌的RANKL mRNA表达的影响
培养72小时后,空白对照组的RANKL mRNA /GAPDH mRNA的相对表达量为1.0203;阳性对照组雌二醇组的RANKL mRNA /GAPDH mRNA的相对表达量为0.8907,与空白对照组比较抑制了RANKLmRNA的表达,差异有显著性(P<0.05);补骨脂素组的RANKLmRNA /GAPDHmRNA的相对表达量为0.8374,与空白对照组比较抑制了RANKLmRNA的表达,差异有显著性(P<0.05),与雌激素组比较无明显差别。
各组OPG/RANKL比值的比较结果是:补骨脂素组与空白对照组比较OPG/RANKL值增加,差别有统计学意义(P<0.05)。
4补骨脂素对大鼠成骨细胞分泌骨形态发生蛋白(BMP-2)的影响
通过免疫组化方法,在倒置相差显微镜下观察,每个低倍镜下(200×)数阳性细胞数,补骨脂素组平均每个低倍镜视野下细胞阳性率为86.67%,雌激素组为93.33%,空白对照组为33.33%,经统计学分析,补骨脂素组与空白对照组比较,BMP-2的表达明显升高,与雌激素组比较无明显差别。
结论
1异欧前胡素作用48小时后,浓度为1×10-9 mol/L~1×10-8 mol/L有促增殖作用(P<0.05);72h时,浓度为1×10-8 mol/L~1×10-7 mol/L有促增殖作用(P<0.05)。
2异欧前胡素作用72小时,浓度1×10-6mol/L~1×10-5mol/L的异欧前胡素能够提高碱性磷酸酶的活性,促进成骨细胞的分化。
3补骨脂素能够上调OPGmRNA的表达,下调RANKLmRNA的表达并使得OPG/RANKL比值增大,这说明香豆素类化合物有可能是通过促进骨形成抑制骨吸收达到防治骨质疏松目的。
4补骨脂素与空白对照组比较能促进成骨细胞分泌骨形态发生蛋白,有统计学意义。说明补骨脂素有可能是通过促进细胞分泌骨形态发生蛋白来发挥其促进骨形成作用。
5从分子生物学角度为香豆素类化合物防治骨质疏松提供一个理论支持。
Objective: With the arrival of the aging society, more and more attention is drawn to the aging problems. Osteoporosis was an important disease affecting human health,which is related to aging. Till now about 2 billion people are infected with Osteoporosis in the world, and its incidence rate is high. A primary analysis of the main statistics of 2000 census, in China about 8800 million people(about occupide 6.6% of population) suffering from Osteoporosis,especially thoses people whose age is in 60~69.it is estimated that the medical care expenses on the treatment of Osteoporosis is about 50 billion rmb at least every year. Osteoporosis, along with it's searious complication and fractures, is severly threatening the wrinkly's health. So it is urgent affairs to find out effective drugs and methods to prevent and treat osteoporosis. Bone absorptioninhibitor drugs and bone formationacceleration drugs are two kinds of anti-osteoporosis drugs. Hormone Replacement Therapy is more commonly used , which could decrease bone mineral loss in Post-menopause Women and improve the density of bone, but promote endometrial hyperplasia, liver damage, venous embolization,vessels diseases and breast cancer.
Phytoestrogen (PE) is a group of natural non steroid compound which displays estrogen like activity because of their structural similarity to human estrogens and exhibits high affinity binding to estrogen receptor beta. PE could improvement perimenopause syndrome,decrease the blood lipid level, prevent osteoprosis and urinary incontinence. Substitute for estrogen in preventing osteoprosis is a hopeful application field for PE. Traditional Chinese drugs Psoralea fruit can improve Yangqi of spleen and kidney. Modern pharmacological research shows the water soluble extractive of Psoralea has the effect on the bone turnover.The acetone-extract from Psoralea fruits can increase bone strength,improve the phosphate in blood. The model of rats osteoprosis were orally injected into the stomach by psoralea compound preparation, decrease alkaline phosphatase(ALP) leavel to normal, decrese Ca/cr and HOP/cr leavels in urine, inhibit absorbtion of bone, the rate of bone formation is eventually greater than bone absorption. Psoralen was one of active component in psoralea. Psoralen has the effects on stimulating the proliferation and maturation of cultured osteoblasts in vitro and promoting typeⅠcollagen (COLI)synthesis. The intracellular signal transduction mechanism of the psoralen to promote the growth of the osteoblasts is not clear. Based on the previous research, we explore the molecular mechanisms biology for psoralen preventing osteoprosis. In order to provide theoretical basis for clinical preventing osteoprosis.
Methods:
1 Cell culture: Improved tissue block culture, to demesh and cultivate osteoblast from cranial bone of newly born SD rats.By ading different concentrations of isoimperatorin (1×10-5 mol/L ~1×10-9 mol/L ) to the nutrient medium of osteoblast it can be observed the alteration of the shape and quantity of cells using inverted phase contrast microscope.
2 Cell proliferation: It can be inspected that the effect of isoimperatorin on the proliferation of osteoblast in 24 h ,48 h and 72 h by MTT methods with the contrast of the group of dealing with estrogen and control group.
3 Cell differentiation: It can be detected that the change of the activity of ALP in osteoblast of the group of dealing with isoimperatorin in24h,48h,72h byρ-nitrophenyl phosphate(рNPP) disodium matrix dynamics methods with the contrast of the group of dealing with estrogen.
4 Cell factors: It can be detected that the expression of Osteoprotegerin (OPG) mRNA, and receptor activator of nuclear factor–κB(RANKL)mRNA of the group of dealing with psoralen in 72 h via RT-PCR with the contrast of the group of dealing with estrogen and control group.
5 Cell protein: It can be detected that the expression of Bone morphogenetic protein (BMP-2) of the group of dealing with psoralen in 72h via immunohistochemistry with the contrast of the group of dealing with estrogen and control group.
Results:
1 The effect of estrogen,as positive control ,on the proliferation and differentiation of the osteoblast
1.1 Cell morphology observation of estrogen group,as positive control
The osteoblast cells which is inoculated is globular at first and then floats in culture fluid . Subsequently it is adherent,it will expand in 24 h.The shape of expanded cell is irregular with a appearance of triangle. After 48 h~96 h,osteoblast shows on long fusiform and trabs shape and mixes together and the boundary is vague between cells. Osteoblast shows slabstone shape after 120 h. If you keep on culturing cell, cells will form cell nodule and opaque mineral nodus with accumulating of collagen and calcium salts. When you culture the 20th generation, the volume of the cell is larger than normal, periplast is more subtile than normal,the speed of cleavage is slower and other phenomena which are signs of aging. Osteoblasts are more intensive in estrogen than the blank group. Also its intercellular space is smaller than those of the blank.
1.2 The effect of estrogen,as positive control on the proliferation of osteoblast
After being cultivated 24 h ,contrasted with control group, the concentrations of 1×10-5mol/L, 1×10-7 mol/L, 1×10-8 mol/L can promote the proliferation of osteoblast (P<0.05); After being cultivated 48 h, the concentrations of 1×10-6mol/L,1×10-8 mol/L,1×10-9mol/L can urge the proliferation of osteoblast (P<0.05); After being cultivated 72 h, the concentratons of 1×10-5 mol/L~1×10-7 mol/L estrogen can promote the proliferation of osteoblast (P<0.05) .
1.3 The effect of estrogen on the ALP of osteoblast
After being cultivated 48 h, contrasted with control group, the concentratons of 1×10-5 mol/L~1×10-6 mol/L can promote the differentiation of osteoblast (P<0.05); after being cultivated 72 h, 1×10-5mol/L~1×10-6mol/L concentrations can urge the differentiation of osteobalst(P<0.05)
2 The effect of isoimperatorin ,as one of the phytoestrogen ,on the proliferation and differentiation of the osteoblast
2.1 Cell morphology observation of the isopsoralen group The phenomenon is similar to estrogen group.
2.2 The effect of isoimperatorin on the proliferation of osteoblast After cultivated 24 h ,contrasted with control group, none of the concentration can promote the proliferation of osteoblast (P>0.05);After cultivated 48h,1×10-9mol/L~1×10-8mol/L concentrations can urge the proliferation of osteoblast(P<0.05);after cultivated 72h, 1×10-8mol/L~1×10-7mol/L concentration can urge the proliferation of osteoblast(P<0.05).
2.3 The effect of isopsoralen on the ALP of osteoblast Contrasted with control group, after cultivated 72h 1×10-6 mol/L~1×10-5mol/L can urge the differentiation of osteobalst(P<0.05).
3 The effect of psoralen on the expression of OPG mRNA in osteobalst
After cultivated 72 h ,the relative quantity of OPG mRNA/GAPDH mRNA expressions in the blank group, in the psoralen group and in the estrogen group are 0.6048, 1.0794 and 1.3395. There is significant difference between psoralen group and the blank group(P<0.05). The expression of OPG mRNA in estrogen group is higher than that in black group(P<0.05). There is no significant difference between estrogen group and psoralen group.
4 The effect of paoralen on the expression of RANKL mRNA in osteobalst
After cultivated 72 h ,the relative quantity of RANKLmRNA/GAPDHmRNA expressions in the blank group ,in the psoralen group and in the estrogen group are 1.0203, 0.8374 and 0.8907. There is significant difference between psoralen group and the blank group(P<0.05). The expression of RANKLmRNA in estrogen group is higher than that in black group(P<0.05). There is no significant difference between estrogen group and psoralen group.
5 The effect of paoralen on the relative quantity of OPG/RANKL in osteobalst
After cultivated 72 h, the relative quantity of VOPG / VRANKL in the blank group ,in the psoralen group and in the estrogen group are 0.599, 1.282 and 1.513. There is significant difference between psoralen group and the blank group(P<0.05). psoralen increased VOPG / VRANKL.
6 Effects of psoralen on the expression of bone morphogenetic protein 2 of osteoblast
the expression of bone morphogenetic protein 2 was tested by immunohistochemistry method.The posotive rates of osteoblast cells in psoralen group is 86.67%, 93.33% in E2 and 33.33% in black group. to compare the black group , psoralen can significantly enhance the expression of BMP-2.
Conclusion:
1 Certain dose of isopsoralen as phytoestrogen, can promote the proliferation of osteoblast.
2 Certain dose of isopsoralen urge the differentiation of osteoblast.
3 The influence of psoralen on bone may be achieved through the pathway of promoting bone formation and inhibiting bone absorption.
4 The influence of psoralen on bone maybe achieved through increasing the expression of OPG mRNA , decreasing the expression of RANKL mRNA,and increasing the rate of VOPG / VRANKL.
5 BMP may be the critical protein in the effection of Phytoestrogen on preventing osteoprosis. The influence of psoralen on bone maybe achieved through increasing the expression of BMP-2
引文
1 张润荃,史凤芹,庞淑珍 等.补骨脂对分离破骨细胞作用的研究.现代口腔医学杂志, 1995, 9(3):136~138
2 林举择, 陈升恺, 罗家栋. 补骨脂注射液对体外培养大鼠成骨细胞增殖的影响.中医正骨,2004, 16(6): 6~7
3 王建华,李恩.大豆甙元对大鼠成骨细胞增殖与分化的影响.天然产物研究与开发, 2003, 15(2):36~39
4 王建华,李恩.大豆甙元对大鼠成骨细胞碱性磷酸酶活性的影响. 中药药理与临床, 2003, 19(4):23~25
5 秦路平, 张汉明, 张卫东 等. 蛇床子素和蛇床子总香豆素对肾阳虚大鼠血清甲状腺素和促甲状腺激素的影响. 中国中西结合杂志, 1996, 16(9):552~553
6 谢梅林, 周佳, 朱路佳. 蛇床子总香豆素对去卵巢大鼠骨质疏松的影响. 苏州大学学报(医学版), 2005, 25 (3):783
7 liqingnan, liangnianci, wutie. Effects of total coumarings of Fructus Cnidii on skeleton of ovariectomized rats. Acta Pharmacologica Sinca, 1994, 15(6):528~532
8 Yashiyuki Kimura, Hiromichi Okuda. Histamine-release effectors from Angelica dahurica var dahurica root . Nat prod, 1997, 60:249
9 重庆市银屑病防治协作组, 口服川白芷至几家黑光照射治疗银屑病159例疗效观察.中华皮肤科杂志, 1981, 14(3):129
10 张国威, 王光超, 周永华. 光化学疗法治疗银屑病——白芷光敏丸与8-MOP的比较. 中华医学杂志, 1983,63(1):16.
11 Kimura roshiyuki, Ohminami Hiroji, Arichi Hioleko, et al. Effects of various coumarins from roots Angelica dahurica on actions of adrenaline, ACTH and insulin. Planta Med, 1982, 45(3):183.
12 国家中医药管理局中草药情报中心站台. 植物药有效成分手册. 人民卫生出版社, 1986, 603.
13 嵇扬. 药物对TNF诱导的牛脑微血管平滑肌细胞增殖的拮抗作用. 药学学报, 1994, 29(2):86.
14 潘龙刚. 白芷光敏胶囊加黑光治疗银屑病的研究. 中成药研究, 1983, 3:30.
15 李健斋,魏明竟, 编. 现代临床生化检验学.人民军医出版社,2001,7:16~21
1 王建华, 王艳, 潘永梅. 补骨脂素对大鼠成骨细胞增殖与分化的影响. 天然药物研究与开发, 2007, 19, (5):844~846
2 王建华, 尹智炜. 补肾方药对去卵巢大鼠骨密度及血清雌激素水平影响的实验研究. 河北中医药学报, 2003, 18 (3): 6~7
3 1 imonet WS, Lacey DL, Dunstan CR, et al. Osteopritegerin a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309~319
4 izuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor osteopritegerin Biochem Biophys Res Commun, 1998, 247: 610~615
5 olloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res, 2002, 17(2): 200~209
6 ucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998, 12: 1260~1268
7 zuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commum, 1998, 247: 610~615
8 u H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteopritegerinligand . Proc Natl Acad Sci USA, 1999, 96: 3540~3545
9 iotani A, Takami M, Itoh K, et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Biochem Biophys Res Commun , 2001, 268(2): 137~146
10 kahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRAHCE/RANKL, regulates osteoclast differentiation and function. Cells, 1999, 256: 449~455
11 fbauer LC, Khisla S, Dunstan CR,et al. The roles of isteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res, 2000, 15: 2~12.
12 刘亦恒, 臧洪敏, 张海英, 陈君长 等. 淫羊藿总黄酮对成骨细胞中 OPG 和 RANKLmRNA 基因表达影响的实验研究. 中药材, 2005, 28(12): 1076~1078
1 Nussenbaum B, TeknosTN, Chepeha D B. Tissue engineering: the current status of this futuristic modality in head neck reconstruction.CurrOpin OtolaryngolHead Neck Surg, 2004, 12(4): 311~315
2 张勇, 马平, 刘健 等. 去势大鼠骨中 BMP-2、BMP-7 基因表达. 第四军医大学学报, 2000, 21(1): 125~126
3 Suzawa, Miyuki, Takeuchi, et al. Extracellular Matrix Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Osteoblastid Cells in Vutro. Endocrinology, 1994, 140(5): 2125~2133
4 Chen D, Harris MA, et al. BMP-2 enhances BMP-3, BMP-4 and bone cell differetiation marker genes expression during the induction of mineralizal bone matix formation in cultures of fetal fat calvaria osteoblasts. Calcify TissueInt, 1966, 113(5): 212~213
5 张子军, 卢世璧, 王继芳 等.骨缺损中内源性的分布及其作用. 中华外科杂志, 1996, 10(34): 569~599
6 Onishi Y, Nagamine Y, et al. Distinct and Overlapping Patterns of Localization of Bone Morphogenetic Protein (BMP) Family Members and a BMP Type II Receptor During Fracture Healing in Rats. Bone, 1998, 22(6): 605~612
7 Soutar RL, Dillon JM, Brown D, et al. Cytokine expression in multiple myelom a and monoclonal gammopathy:analysis by reverse transcription/polymerase chain reaction and quantitative PCR. Leuk Lym phoma, 1996, 24: 111~120
8 卢卫忠, 唐康来, 杨柳 等. TGF-β 对成骨细胞的作用. 第三军医大学学报, 2000, 22: 94~96
9 王洪复, 金蔚芳, 高建军. 骨质疏松症防治药物的体外细胞药效评价. 中国骨质疏松杂志, 1999, 5(2): 58~62
10 Wonzey JM, Rosen V Bone morphogenetic protein and bone morphogentic protein gene family in bone formation and repair. Clin Orthop, 1998, 346: 26~37
11 Harris SE, Feng JQ, Harris MA, et al. Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulates BMP-2 promoter activity in primary fetal rat calvarial osteoblast cultures. Mol Cell Differ, 1995, 3: 137~155
12 Chen D, Harris MA, Rossini G, et al. Bone morphogentic protein 2(BMP-2)enhances BMP-3,BMP-4 and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in culture of fetal rat calvarial osteoblasts. Calcif Tissue Int, 1997, 60: 283~290
13 张子军, 卢世璧, 王继芳 等. 骨缺损中内源性 BMP 的分布及其作用. 中华外科杂志, 1996, 10 (34): 569~599
14 Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defec, Bone Joint Surg Br. 1999, 81(4): 710~718
15 Steven RC, Douglas CB. Do statins prevent both cardiovascular diseaseandfracture. JAMA, 2000, 238: 3255~3258
16 张勇, 马平, 刘建 等. 去势大鼠骨中BMP-2, BMP-7基因表达. 第四军医大学学报, 2000, 21(1): 125~126
1 Nakashima K, Zhou X, Kunkel G, et al. The novel zinfinger containing transcription factor osterixis requiread for osteoblast differentiation and bone for mation. Cell, 2002, 108:17~29
2 Akiyama H, Chaboissier MC, Martin JF, et al. The tran- scription factor Sox9 has essentional roles insuccessive steps of the chondrocyted if ferentiation pathway and is required for expression of Sox5 and Sox6. GenesDev, 2002, 16(21): 2813~2828
3 Mitlak BH, WilliamsDC, BryantHU,etal. Intermittent administration of bovine PTH-(1-34) increases serum 1,
25-dihydroxyvitamin D concenrations and spinal bone density in senile(23 month)rats. J BoneMinerRes, 1992, 7(5): 479 ~480
4 Shearer MJ. Role of vitaminK and Gla proteins in the pathophysiology of osteoporosis and vascular calcification.Curr Opin ClinNutrMetab Care, 2000, 3(6): 433~ 438
5 Chen J, Thomas HF, Jin H,et al. Expression of ratbone sialoprotein promoter in transgenicmice. JBoneMinerRes, 1996, 11(5): 654~664.
6 周国林, 石关桐 等. 绝经后妇女骨密度、体重指数、体脂和雌激素分泌的关系. 中国骨质疏松杂志, 2005, 11(1): 34~37
7 Wu F, Ames R, Clearwater J, et al. Prospective10-year study of thedeterminants of bone density and bonc loss in normal postmenopausalwomen, includingthe effect of hormone replacementtherapy. Clin En-docrinol (Oxf), 2002, 56: 703~71
8 Reid IR, Ames RW, Evans MC, et al. Determinants of the rate ofbone loss in normal postmenopausal women.JClin EndocrinolMetab, 1994, 79: 950~954
9 黄苏平, 肖林榕 等. 骨质疏松症中医药研究进展. 福建中医学院学报, 2006, 16(1): 67~69
10 李海凤, 周伟生. 骨质疏松症的中西医病因病机研究进展 . 现 代 临 床 医 学 生 物 工 程 学 杂 志 , 2003, 9(5) : 4502~455.
11 沈霖, 武嘉林 等. 阿胶强骨口服液含药血清对胎鼠成骨细胞护骨素及护骨素配体 mRNA 表达的影响. 第八次全国中西医结合虚证与老年医学学术研讨会论文集,P72~76
12 李昌龙, 鞠大宏 等. 补肾健骨方对卵巢切除所致骨质疏松大鼠外周血清中 TNF-α的影响. 中国中医基础医学杂志, 2005, 11(1): 32~33
13 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞Smad2 mRNA表达影响的研究. 中医药学刊, 2005, 23(4): 618~620
14 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞 TGF-β1 表达的影响. 辽宁中医杂志, 2005, 32(2): 100~102
15 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞信号转导分子 Smad4 表达的影响. 中国老年学杂志,2005, 25(3): 289~291
16 曹亚飞, 刘红敏, 刘庆思. 骨质疏松症的中医证型与治疗原则探讨. 中国骨质疏松杂志, 2002, 8(4): 36
17 Erlebacher A, Derrnck R. Indreased expression of TGF-βin osteoblast results an osteoporosis-like phenitype. Journal of Cell Biology, 1996, 132: 192~199
18 Heldin C H, MiyazonoK, ten Dijke P. TGF-βsignaling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390: 465~471
19 ShiY A, HataRS, Lo J, et al. A structuralbasis formutational inacti-vation of the tumor suppressorSmad4. Nature, 1997; 388: 87~93
20 Heldin CH, Miyazono K, Ten Dijke P. TGF-βsignaling from cellmembrane to nucleus through SMAD proteins. Nature, 1997, 390: 465~471
21 Sakou T, Onishi T, Yamamoto T, et al. Localization of Smads, theTGF-beta family intracellular signaling components during endochondral ossification. BoneMinerRes, 1999, 14: 1145~52
22 任艳玲, 郑洪新, 杜松 等. 补肾益气生精中药对去卵巢大鼠骨质疏松发生机制的调节作用. 北京中医药大学学报, 2006, 29(2): 94~97
23 石印玉, 詹红生 等. 补肾中药对成骨细胞维生素 D 受体与核心结合因子α1蛋白表达的影响. 上海中医药学杂志,2005, 39(11): 46~49
24 Mitlak BH, WilliamsDC, BryantHU, et al. Intermittent adminis-tration of bovine PTH-(1-34) increases serum 1,
25-dihydroxyvita-min D concenrations and spinal bone density in senile(23 month)ats. BoneMinerRes, 1992, 7(5): 479~ 484.
25 Norman AW, Bishop JE, BulaCM, et al. Molecular tools for studyof genomic and rapid signal transduction responses initiated by1 alpha, 25 (OH) (2)-vitamin D (3). Steroids, 2002, 67(6): 457 ~466.
26 Lian JB, Stein GS, Stein JL, et al. Osteocalcin gene promoter:unlocking the secrets for regulation ofosteoblastgrowth and differ-entiation. CellBiochem Supp, 1998, 30(31): 62 ~72.
27 BanerjeeC, HiebertSW, Stein JL,et al. AnAML-1 consensus sequence bind sosteoblast-specific complexand transcriptionallyactivates the osteocalcin gene. Proc Nat CellBio, 1996, 93(10): 4968~4973.
28 Ducy P, ZhangR, GeoffroyV, et al. Osf2 /CbfαⅠ: a transcriptional activator of osteoblast differentiation. Cell, 1997, 89(5): 747~754.
29 Banerjee C, McCabe LR, Choi JY, et al. Runthomology domainproteins in osteoblast differentiation: AML3 /CBFA1 ia a majoromponent ofa bone-specific complex. CellBiochem, 1997, 66(1): 1~8
30 郑云霞, 杨仁旭, 陈红 等. 滋肾丸对去卵巢骨质疏松雌鼠的骨组织形态学的改善作用即机制的实验研究. 四川中医, 2006, 24(2): 16~18
31 刘亦恒, 臧洪敏, 张海英 等. 淫羊藿总黄酮对大鼠成骨细胞中 OPG 和 RANKL 基因表达影响的实验研究. 中药材, 2005, 28(12): 1076~1078
32 刘亦恒, 臧洪敏, 张海英 等. 淫羊藿总黄酮对大鼠成骨细胞代谢调控的机制研究. 中国中药杂志, 2006, 31(6): 4 87~490
33 李朝阳, 吴铁, 李青南 等. 蛇床子总香豆素与尼尔雌醇对去卵巢大鼠骨代谢的影响. 中国药理学报, 1997, 18:286~288
34 胡彬,吴翠环 等. 蛇床子素对大鼠成骨细胞中 OPG 和RANKL 基因 mRNA 表达的影响. 中国骨质疏松杂志,2004, 10(4): 415~419
35 翁德宝, 管笪, 徐颖治. 鸡冠花的营养成分分析. 营养学报, 1995, 17(1): 59~62.
36 李万里, 原志庆, 刘晓丽. 鸡冠花提取物与钙对氟中毒大鼠骨密度及尿矿物质含量的影响. 卫生研究, 1999, 28(4): 230~232.
37 李万里,田玉慧 等. 鸡冠花黄酮类对成骨细胞矿化和IGF-1 的作用. 中国公共卫生, 2003, 19(11): 1392~1393
38 卢建华, 吴承亮, 倪佳宝 等. 红曲对去卵巢大鼠 BMP-2表达及成骨细胞增殖影响的实验研究. 中国骨伤, 2005, 18(1): 25~27
1 阮博, 孔令义. 补骨脂素化学成分的研究.中药研究与信息, 2005, 7(4): 7~9
2 郭江宁. 补骨脂抗氧化与抗癌活性成分的研究. 沈阳药科大学博士学位论文
3 沈建良, 黄友章, 杨平地. 预激态补骨脂素对白血病原代细胞杀伤作用的研究. 临床肿瘤学杂志, 2006, 11(7): 502~508
4 向阳, 葛永亮, 张德杰 等. 补骨脂素加长紫外线对NB4,K562 白血病细胞株作用. 第四军医大学学报, 2006, 27(7): 609~611
5 蔡宇,陈冰,张荣华 等. 补骨脂素对 HL60 细胞凋亡及细胞内 Ca2+浓度影响的探讨. 中国肿瘤临床, 2006, 33(2): 64~66
6 胡云, 吴军正, 陈建元. 补骨脂素类药物对宫颈鳞癌 Hela细胞恶性表型的影响. 中国中医药科技, 1999, 6(3): 157~158
7 崔昱, 秦元华, 张晓林等. 鸦胆子与补骨脂素对大鼠肺孢子虫肺炎防治作用. 中国公共卫生, 2006, 22(6): 684~686
8 秦元华, 崔昱, 任一鑫. 中药鸦胆子与补骨脂素对卡氏肺孢子虫病大鼠免疫调节的影响. 中国寄生虫学与寄生虫病杂志, 2006, 24( 1): 59~61
9 邓时贵, 李爱群, 欧润妹 等. 补骨脂素总香豆素的平喘作用.中药现代应用药学杂志, 2001, 18(6): 439~440
10 张军, 马锡金, 李宗友. 补骨脂种子提取物的粗组分对骨钙化的影响. 国外医学中医药分册, p55
11 林举择, 陈升恺, 罗家栋, 补骨脂注射液对体外培养大鼠成骨细胞增殖的影响. 中医正骨, 2004, 16(6 ): 6~7
12 邓萍香, 徐敏. 补骨脂对去卵巢大鼠骨转换及血脂代谢影响的实验研究.新中医, 2005,37(7): 94~96
13 寿清耀, 万丽, 谢秀琼. 补骨脂治疗骨质疏松的的物质基础研究. 成都中医药大学硕士论文, p44
14 徐建国.补骨脂对酪氨酸酶激活作用.中草药, 1991, 22(40): 168~169
15 邓萍香, 徐敏. 补骨脂对去卵巢大鼠骨转换及血脂代谢影响的实验研究. 新中医, 2005, 37(7): 94~96
16 蔡宇. 补骨脂素逆转人乳腺癌细胞多要耐药性的研究. 肿瘤, 2004, 24(3): 240~241
17 蔡宇, 蔡天革. 补骨脂素逆转多药耐药细胞系 K562/ADR耐药性研究. 中国药理学通报, 2003, 19(10): 1164~1166
18 周欣初. 中草药与化妆品. 1987, 85~86.
2 林举择, 陈升恺, 罗家栋. 补骨脂注射液对体外培养大鼠成骨细胞增殖的影响.中医正骨,2004, 16(6): 6~7
3 王建华,李恩.大豆甙元对大鼠成骨细胞增殖与分化的影响.天然产物研究与开发, 2003, 15(2):36~39
4 王建华,李恩.大豆甙元对大鼠成骨细胞碱性磷酸酶活性的影响. 中药药理与临床, 2003, 19(4):23~25
5 秦路平, 张汉明, 张卫东 等. 蛇床子素和蛇床子总香豆素对肾阳虚大鼠血清甲状腺素和促甲状腺激素的影响. 中国中西结合杂志, 1996, 16(9):552~553
6 谢梅林, 周佳, 朱路佳. 蛇床子总香豆素对去卵巢大鼠骨质疏松的影响. 苏州大学学报(医学版), 2005, 25 (3):783
7 liqingnan, liangnianci, wutie. Effects of total coumarings of Fructus Cnidii on skeleton of ovariectomized rats. Acta Pharmacologica Sinca, 1994, 15(6):528~532
8 Yashiyuki Kimura, Hiromichi Okuda. Histamine-release effectors from Angelica dahurica var dahurica root . Nat prod, 1997, 60:249
9 重庆市银屑病防治协作组, 口服川白芷至几家黑光照射治疗银屑病159例疗效观察.中华皮肤科杂志, 1981, 14(3):129
10 张国威, 王光超, 周永华. 光化学疗法治疗银屑病——白芷光敏丸与8-MOP的比较. 中华医学杂志, 1983,63(1):16.
11 Kimura roshiyuki, Ohminami Hiroji, Arichi Hioleko, et al. Effects of various coumarins from roots Angelica dahurica on actions of adrenaline, ACTH and insulin. Planta Med, 1982, 45(3):183.
12 国家中医药管理局中草药情报中心站台. 植物药有效成分手册. 人民卫生出版社, 1986, 603.
13 嵇扬. 药物对TNF诱导的牛脑微血管平滑肌细胞增殖的拮抗作用. 药学学报, 1994, 29(2):86.
14 潘龙刚. 白芷光敏胶囊加黑光治疗银屑病的研究. 中成药研究, 1983, 3:30.
15 李健斋,魏明竟, 编. 现代临床生化检验学.人民军医出版社,2001,7:16~21
1 王建华, 王艳, 潘永梅. 补骨脂素对大鼠成骨细胞增殖与分化的影响. 天然药物研究与开发, 2007, 19, (5):844~846
2 王建华, 尹智炜. 补肾方药对去卵巢大鼠骨密度及血清雌激素水平影响的实验研究. 河北中医药学报, 2003, 18 (3): 6~7
3 1 imonet WS, Lacey DL, Dunstan CR, et al. Osteopritegerin a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309~319
4 izuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor osteopritegerin Biochem Biophys Res Commun, 1998, 247: 610~615
5 olloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res, 2002, 17(2): 200~209
6 ucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998, 12: 1260~1268
7 zuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commum, 1998, 247: 610~615
8 u H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteopritegerinligand . Proc Natl Acad Sci USA, 1999, 96: 3540~3545
9 iotani A, Takami M, Itoh K, et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Biochem Biophys Res Commun , 2001, 268(2): 137~146
10 kahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRAHCE/RANKL, regulates osteoclast differentiation and function. Cells, 1999, 256: 449~455
11 fbauer LC, Khisla S, Dunstan CR,et al. The roles of isteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res, 2000, 15: 2~12.
12 刘亦恒, 臧洪敏, 张海英, 陈君长 等. 淫羊藿总黄酮对成骨细胞中 OPG 和 RANKLmRNA 基因表达影响的实验研究. 中药材, 2005, 28(12): 1076~1078
1 Nussenbaum B, TeknosTN, Chepeha D B. Tissue engineering: the current status of this futuristic modality in head neck reconstruction.CurrOpin OtolaryngolHead Neck Surg, 2004, 12(4): 311~315
2 张勇, 马平, 刘健 等. 去势大鼠骨中 BMP-2、BMP-7 基因表达. 第四军医大学学报, 2000, 21(1): 125~126
3 Suzawa, Miyuki, Takeuchi, et al. Extracellular Matrix Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Osteoblastid Cells in Vutro. Endocrinology, 1994, 140(5): 2125~2133
4 Chen D, Harris MA, et al. BMP-2 enhances BMP-3, BMP-4 and bone cell differetiation marker genes expression during the induction of mineralizal bone matix formation in cultures of fetal fat calvaria osteoblasts. Calcify TissueInt, 1966, 113(5): 212~213
5 张子军, 卢世璧, 王继芳 等.骨缺损中内源性的分布及其作用. 中华外科杂志, 1996, 10(34): 569~599
6 Onishi Y, Nagamine Y, et al. Distinct and Overlapping Patterns of Localization of Bone Morphogenetic Protein (BMP) Family Members and a BMP Type II Receptor During Fracture Healing in Rats. Bone, 1998, 22(6): 605~612
7 Soutar RL, Dillon JM, Brown D, et al. Cytokine expression in multiple myelom a and monoclonal gammopathy:analysis by reverse transcription/polymerase chain reaction and quantitative PCR. Leuk Lym phoma, 1996, 24: 111~120
8 卢卫忠, 唐康来, 杨柳 等. TGF-β 对成骨细胞的作用. 第三军医大学学报, 2000, 22: 94~96
9 王洪复, 金蔚芳, 高建军. 骨质疏松症防治药物的体外细胞药效评价. 中国骨质疏松杂志, 1999, 5(2): 58~62
10 Wonzey JM, Rosen V Bone morphogenetic protein and bone morphogentic protein gene family in bone formation and repair. Clin Orthop, 1998, 346: 26~37
11 Harris SE, Feng JQ, Harris MA, et al. Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulates BMP-2 promoter activity in primary fetal rat calvarial osteoblast cultures. Mol Cell Differ, 1995, 3: 137~155
12 Chen D, Harris MA, Rossini G, et al. Bone morphogentic protein 2(BMP-2)enhances BMP-3,BMP-4 and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in culture of fetal rat calvarial osteoblasts. Calcif Tissue Int, 1997, 60: 283~290
13 张子军, 卢世璧, 王继芳 等. 骨缺损中内源性 BMP 的分布及其作用. 中华外科杂志, 1996, 10 (34): 569~599
14 Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defec, Bone Joint Surg Br. 1999, 81(4): 710~718
15 Steven RC, Douglas CB. Do statins prevent both cardiovascular diseaseandfracture. JAMA, 2000, 238: 3255~3258
16 张勇, 马平, 刘建 等. 去势大鼠骨中BMP-2, BMP-7基因表达. 第四军医大学学报, 2000, 21(1): 125~126
1 Nakashima K, Zhou X, Kunkel G, et al. The novel zinfinger containing transcription factor osterixis requiread for osteoblast differentiation and bone for mation. Cell, 2002, 108:17~29
2 Akiyama H, Chaboissier MC, Martin JF, et al. The tran- scription factor Sox9 has essentional roles insuccessive steps of the chondrocyted if ferentiation pathway and is required for expression of Sox5 and Sox6. GenesDev, 2002, 16(21): 2813~2828
3 Mitlak BH, WilliamsDC, BryantHU,etal. Intermittent administration of bovine PTH-(1-34) increases serum 1,
25-dihydroxyvitamin D concenrations and spinal bone density in senile(23 month)rats. J BoneMinerRes, 1992, 7(5): 479 ~480
4 Shearer MJ. Role of vitaminK and Gla proteins in the pathophysiology of osteoporosis and vascular calcification.Curr Opin ClinNutrMetab Care, 2000, 3(6): 433~ 438
5 Chen J, Thomas HF, Jin H,et al. Expression of ratbone sialoprotein promoter in transgenicmice. JBoneMinerRes, 1996, 11(5): 654~664.
6 周国林, 石关桐 等. 绝经后妇女骨密度、体重指数、体脂和雌激素分泌的关系. 中国骨质疏松杂志, 2005, 11(1): 34~37
7 Wu F, Ames R, Clearwater J, et al. Prospective10-year study of thedeterminants of bone density and bonc loss in normal postmenopausalwomen, includingthe effect of hormone replacementtherapy. Clin En-docrinol (Oxf), 2002, 56: 703~71
8 Reid IR, Ames RW, Evans MC, et al. Determinants of the rate ofbone loss in normal postmenopausal women.JClin EndocrinolMetab, 1994, 79: 950~954
9 黄苏平, 肖林榕 等. 骨质疏松症中医药研究进展. 福建中医学院学报, 2006, 16(1): 67~69
10 李海凤, 周伟生. 骨质疏松症的中西医病因病机研究进展 . 现 代 临 床 医 学 生 物 工 程 学 杂 志 , 2003, 9(5) : 4502~455.
11 沈霖, 武嘉林 等. 阿胶强骨口服液含药血清对胎鼠成骨细胞护骨素及护骨素配体 mRNA 表达的影响. 第八次全国中西医结合虚证与老年医学学术研讨会论文集,P72~76
12 李昌龙, 鞠大宏 等. 补肾健骨方对卵巢切除所致骨质疏松大鼠外周血清中 TNF-α的影响. 中国中医基础医学杂志, 2005, 11(1): 32~33
13 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞Smad2 mRNA表达影响的研究. 中医药学刊, 2005, 23(4): 618~620
14 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞 TGF-β1 表达的影响. 辽宁中医杂志, 2005, 32(2): 100~102
15 任艳玲, 郑洪新, 杜松 等. 补肾健脾药物血清对大鼠成骨细胞信号转导分子 Smad4 表达的影响. 中国老年学杂志,2005, 25(3): 289~291
16 曹亚飞, 刘红敏, 刘庆思. 骨质疏松症的中医证型与治疗原则探讨. 中国骨质疏松杂志, 2002, 8(4): 36
17 Erlebacher A, Derrnck R. Indreased expression of TGF-βin osteoblast results an osteoporosis-like phenitype. Journal of Cell Biology, 1996, 132: 192~199
18 Heldin C H, MiyazonoK, ten Dijke P. TGF-βsignaling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390: 465~471
19 ShiY A, HataRS, Lo J, et al. A structuralbasis formutational inacti-vation of the tumor suppressorSmad4. Nature, 1997; 388: 87~93
20 Heldin CH, Miyazono K, Ten Dijke P. TGF-βsignaling from cellmembrane to nucleus through SMAD proteins. Nature, 1997, 390: 465~471
21 Sakou T, Onishi T, Yamamoto T, et al. Localization of Smads, theTGF-beta family intracellular signaling components during endochondral ossification. BoneMinerRes, 1999, 14: 1145~52
22 任艳玲, 郑洪新, 杜松 等. 补肾益气生精中药对去卵巢大鼠骨质疏松发生机制的调节作用. 北京中医药大学学报, 2006, 29(2): 94~97
23 石印玉, 詹红生 等. 补肾中药对成骨细胞维生素 D 受体与核心结合因子α1蛋白表达的影响. 上海中医药学杂志,2005, 39(11): 46~49
24 Mitlak BH, WilliamsDC, BryantHU, et al. Intermittent adminis-tration of bovine PTH-(1-34) increases serum 1,
25-dihydroxyvita-min D concenrations and spinal bone density in senile(23 month)ats. BoneMinerRes, 1992, 7(5): 479~ 484.
25 Norman AW, Bishop JE, BulaCM, et al. Molecular tools for studyof genomic and rapid signal transduction responses initiated by1 alpha, 25 (OH) (2)-vitamin D (3). Steroids, 2002, 67(6): 457 ~466.
26 Lian JB, Stein GS, Stein JL, et al. Osteocalcin gene promoter:unlocking the secrets for regulation ofosteoblastgrowth and differ-entiation. CellBiochem Supp, 1998, 30(31): 62 ~72.
27 BanerjeeC, HiebertSW, Stein JL,et al. AnAML-1 consensus sequence bind sosteoblast-specific complexand transcriptionallyactivates the osteocalcin gene. Proc Nat CellBio, 1996, 93(10): 4968~4973.
28 Ducy P, ZhangR, GeoffroyV, et al. Osf2 /CbfαⅠ: a transcriptional activator of osteoblast differentiation. Cell, 1997, 89(5): 747~754.
29 Banerjee C, McCabe LR, Choi JY, et al. Runthomology domainproteins in osteoblast differentiation: AML3 /CBFA1 ia a majoromponent ofa bone-specific complex. CellBiochem, 1997, 66(1): 1~8
30 郑云霞, 杨仁旭, 陈红 等. 滋肾丸对去卵巢骨质疏松雌鼠的骨组织形态学的改善作用即机制的实验研究. 四川中医, 2006, 24(2): 16~18
31 刘亦恒, 臧洪敏, 张海英 等. 淫羊藿总黄酮对大鼠成骨细胞中 OPG 和 RANKL 基因表达影响的实验研究. 中药材, 2005, 28(12): 1076~1078
32 刘亦恒, 臧洪敏, 张海英 等. 淫羊藿总黄酮对大鼠成骨细胞代谢调控的机制研究. 中国中药杂志, 2006, 31(6): 4 87~490
33 李朝阳, 吴铁, 李青南 等. 蛇床子总香豆素与尼尔雌醇对去卵巢大鼠骨代谢的影响. 中国药理学报, 1997, 18:286~288
34 胡彬,吴翠环 等. 蛇床子素对大鼠成骨细胞中 OPG 和RANKL 基因 mRNA 表达的影响. 中国骨质疏松杂志,2004, 10(4): 415~419
35 翁德宝, 管笪, 徐颖治. 鸡冠花的营养成分分析. 营养学报, 1995, 17(1): 59~62.
36 李万里, 原志庆, 刘晓丽. 鸡冠花提取物与钙对氟中毒大鼠骨密度及尿矿物质含量的影响. 卫生研究, 1999, 28(4): 230~232.
37 李万里,田玉慧 等. 鸡冠花黄酮类对成骨细胞矿化和IGF-1 的作用. 中国公共卫生, 2003, 19(11): 1392~1393
38 卢建华, 吴承亮, 倪佳宝 等. 红曲对去卵巢大鼠 BMP-2表达及成骨细胞增殖影响的实验研究. 中国骨伤, 2005, 18(1): 25~27
1 阮博, 孔令义. 补骨脂素化学成分的研究.中药研究与信息, 2005, 7(4): 7~9
2 郭江宁. 补骨脂抗氧化与抗癌活性成分的研究. 沈阳药科大学博士学位论文
3 沈建良, 黄友章, 杨平地. 预激态补骨脂素对白血病原代细胞杀伤作用的研究. 临床肿瘤学杂志, 2006, 11(7): 502~508
4 向阳, 葛永亮, 张德杰 等. 补骨脂素加长紫外线对NB4,K562 白血病细胞株作用. 第四军医大学学报, 2006, 27(7): 609~611
5 蔡宇,陈冰,张荣华 等. 补骨脂素对 HL60 细胞凋亡及细胞内 Ca2+浓度影响的探讨. 中国肿瘤临床, 2006, 33(2): 64~66
6 胡云, 吴军正, 陈建元. 补骨脂素类药物对宫颈鳞癌 Hela细胞恶性表型的影响. 中国中医药科技, 1999, 6(3): 157~158
7 崔昱, 秦元华, 张晓林等. 鸦胆子与补骨脂素对大鼠肺孢子虫肺炎防治作用. 中国公共卫生, 2006, 22(6): 684~686
8 秦元华, 崔昱, 任一鑫. 中药鸦胆子与补骨脂素对卡氏肺孢子虫病大鼠免疫调节的影响. 中国寄生虫学与寄生虫病杂志, 2006, 24( 1): 59~61
9 邓时贵, 李爱群, 欧润妹 等. 补骨脂素总香豆素的平喘作用.中药现代应用药学杂志, 2001, 18(6): 439~440
10 张军, 马锡金, 李宗友. 补骨脂种子提取物的粗组分对骨钙化的影响. 国外医学中医药分册, p55
11 林举择, 陈升恺, 罗家栋, 补骨脂注射液对体外培养大鼠成骨细胞增殖的影响. 中医正骨, 2004, 16(6 ): 6~7
12 邓萍香, 徐敏. 补骨脂对去卵巢大鼠骨转换及血脂代谢影响的实验研究.新中医, 2005,37(7): 94~96
13 寿清耀, 万丽, 谢秀琼. 补骨脂治疗骨质疏松的的物质基础研究. 成都中医药大学硕士论文, p44
14 徐建国.补骨脂对酪氨酸酶激活作用.中草药, 1991, 22(40): 168~169
15 邓萍香, 徐敏. 补骨脂对去卵巢大鼠骨转换及血脂代谢影响的实验研究. 新中医, 2005, 37(7): 94~96
16 蔡宇. 补骨脂素逆转人乳腺癌细胞多要耐药性的研究. 肿瘤, 2004, 24(3): 240~241
17 蔡宇, 蔡天革. 补骨脂素逆转多药耐药细胞系 K562/ADR耐药性研究. 中国药理学通报, 2003, 19(10): 1164~1166
18 周欣初. 中草药与化妆品. 1987, 85~86.